摘要
【目的】观察合生元对大肠癌患者缓解术后化疗相关不良反应及增强化疗效果的作用。【方法】选取2017年6月到2018年9月在同济大学附属第十人民医院行XELOX方案(奥沙利铂+卡培他滨)化疗的大肠癌术后患者40例,随机分为干预组和对照组。干预组口服合生元制剂2个月,对照组口服安慰剂2个月。在患者首次化疗前和干预2个月后进行临床随访并收集临床检验结果。【结果】干预组发生化疗相关性腹泻(CID)2例,对照组9例,差异有统计学意义(P=0.013)。临床随访结果显示,干预组发生食欲下降2例,发生恶心呕吐3例,对照组分别为17例和10例,组间差异有统计学意义(P<0.001,P=0.018)。在便秘、腹痛、骨髓抑制、肿瘤标志物升高和粪隐血方面,两组间差异均无统计学意义(P>0.05)。干预组患者前白蛋白、白蛋白、谷草转氨酶(AST)和CD4/CD8等4项指标检测结果均优于对照组(P分别为<0.001、0.006、0.035、0.043)。其他临床指标差异均无统计学意义(P>0.05)。治疗过程中,患者未出现与合生元相关不良反应。【结论】合生元有助于改善大肠癌患者术后化疗相关不良反应,能够提高化疗患者的生活质量。
[Objective]To observe the effect of synbiotics in alleviating chemotherapy-related toxic and side effects and enhancing the effect of post-operative chemotherapy.[Methods]A total of 40 postoperative colorectal cancer patients who received XELOX chemotherapy(oxaliplatin+capecitabine)in Shanghai Tenth People′s Hospital from June 2017 to September 2018 were selected and randomly divided into the synbiotics group and placebo group.The synbiotics group took synbiotics preparations orally for 2 months,while the placebo group took placebo orally for 2 months.Clinical follow-up visits and clinical test results were collected before the first chemotherapy and 2 months after the intervention.[Results]Chemotherapy-associated diarrhea(CID)occurred in 2 patients in the synbiotics group,compared with 9 patients in the placebo group,showing a statistically significant difference(P=0.013).Clinical follow-up results showed that 2 patients in the synbiotics group had decreased appetite,3 patients had nausea and vomiting,and 17 and 10 patients in the placebo group,respectively.The incidence of decreased appetite and nausea and vomiting was significantly reduced in the synbiotics group,and the difference between the groups was statistically significant(P<0.001,P=0.018).There was no significant difference between the two groups in constipation,abdominal pain,bone marrow suppression,increased tumor markers,and fecal occult blood(P>0.05).The results of pre-albumin,albumin,aspartate transaminase(AST)and CD4/CD8 in the synbiotics group were all better than those in the placebo group(P<0.001,P=0.006,P=0.035,P=0.043).There was no statistical difference in other clinical indicators(P>0.05).During the treatment,no adverse reactions related to synbiotics were observed in the patients.[Conclusion]Synbiotics can improve the toxic and side effects of postoperative chemotherapy for colorectal cancer and improve the quality of life for patients undergoing chemotherapy.
作者
鲁贺磊
秦环龙
LU He-lei;QIN Huan-long(Tenth People′s Hospital,Institute of Intestinal Diseases,Tongji University School of Medicine,Shanghai 200072,China)
出处
《上海预防医学》
CAS
2019年第10期799-802,共4页
Shanghai Journal of Preventive Medicine
基金
益生菌与慢性疾病临床研究项目(JYJSKF-2018080001)
关键词
合生元
大肠癌
化学治疗
化疗相关性腹泻
synbiotics
colorectalcancer
chemotherapy
chemotherapy-related diarrhea
